NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
NEUROCRINE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$136.98+1.27 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $14.27B
- P/E (TTM)
- 20.1
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
99.5%
101M of 102M shares
Institutional holders
775
147 new, 63 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 40 sales
Net sold $77.87M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Dodge & Cox | 5,534,624 | 5.60% | 13G (passive) | Mar 31, 2025 |
| JPMorgan Chase & Co. | 5,300,390 | 5.20% | 13G (passive) amendment | Sep 30, 2026 |
| Vanguard Capital Management | 5,257,941 | 5.23% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 12,052,271 | 12.10% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NBIX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,711,607 | 13.49% | $2.31B | +326,000 | 0.03% |
| JPMorgan Chase & Co | 6,398,674 | 6.29% | $1.09B | +956,607 | 0.06% |
| Dodge & Cox | 5,584,707 | 5.49% | $941.22M | +123,670 | 0.49% |
| Vanguard Portfolio Management LLC | 4,974,083 | 4.89% | $838.31M | +247,739 | 0.04% |
| Vanguard Capital Management LLC | 4,545,339 | 4.47% | $766.05M | +33,435 | 0.02% |
| State Street Corp | 4,385,598 | 4.31% | $739.13M | +31,072 | 0.02% |
| Aqr Capital Management LLC | 3,818,037 | 3.76% | $643.47M | −1,120,930 | 0.22% |
| Renaissance Technologies LLC | 2,335,897 | 2.30% | $393.68M | −83,000 | 0.54% |
| Geode Capital Management, LLC | 2,138,777 | 2.10% | $359.61M | +2,105 | 0.02% |
| Two Sigma Investments, LP | 2,076,260 | 2.04% | $349.92M | −984,310 | 0.25% |
| Vestal Point Capital, LP | 1,880,000 | 1.85% | $316.85M | +630,000 | 7.40% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,494,259 | 1.47% | $251.86M | +446 | 0.25% |
| Morgan Stanley | 1,318,607 | 1.30% | $222.23M | +99,411 | 0.01% |
| Rtw Investments, LP | 1,267,925 | 1.25% | $213.69M | +205,853 | 1.82% |
| Northern Trust Corp | 1,259,717 | 1.24% | $212.31M | +16,887 | 0.02% |
| Invesco Ltd. | 1,077,317 | 1.06% | $181.57M | +721,308 | 0.01% |
| Charles Schwab Investment Management Inc | 974,279 | 0.96% | $164.20M | +71,491 | 0.02% |
| Norges Bank | 973,880 | 0.96% | $164.13M | New | 0.02% |
| First Trust Advisors LP | 923,125 | 0.91% | $155.58M | −36,092 | 0.09% |
| Dimensional Fund Advisors LP | 732,877 | 0.72% | $123.53M | +21,115 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 775 | 101M | 99.5% | 147 / 321 | 225 / 63 | 13M | 11M |
| Q1 2026 | 699 | 100M | 98.5% | 84 / 306 | 216 / 110 | 24M | 13M |
| Q4 2025 | 732 | 99M | 97.7% | 139 / 275 | 224 / 41 | 11M | 13M |
| Q3 2025 | 650 | 102M | 100.0% | 121 / 220 | 219 / 50 | 12M | 10M |
| Q2 2025 | 586 | 99M | 97.5% | 78 / 223 | 221 / 70 | 14M | 11M |
| Q1 2025 | 586 | 96M | 94.8% | 75 / 187 | 254 / 83 | 13M | 11M |
| Q4 2024 | 601 | 95M | 93.3% | 113 / 214 | 211 / 74 | 13M | 12M |
| Q3 2024 | 576 | 95M | 93.2% | 71 / 236 | 202 / 84 | 23M | 11M |
| Q2 2024 | 595 | 96M | 94.9% | 80 / 254 | 189 / 68 | 9M | 13M |
| Q1 2024 | 589 | 100M | 98.8% | 90 / 227 | 208 / 49 | 11M | 7M |
| Q4 2023 | 555 | 97M | 95.3% | 94 / 206 | 199 / 43 | 14M | 9M |
| Q3 2023 | 512 | 92M | 90.4% | 90 / 159 | 197 / 30 | 10M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NBIX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Dodge & Cox Stock Fund | 3,964,000 | 3.90% | $668.07M | 0.56% | Jun 30, 2026 |
| iShares Core S&P Mid-Cap ETF | 3,441,037 | 3.39% | $579.94M | 0.47% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,193,267 | 3.14% | $538.18M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,304,996 | 2.27% | $388.47M | 0.21% | Jun 30, 2026 |
| JPMorgan Growth Advantage Fund | 1,358,475 | 1.34% | $228.95M | 1.02% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,329,829 | 1.31% | $224.12M | 0.48% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,152,825 | 1.13% | $194.29M | 0.20% | Jun 30, 2026 |
| JPMorgan Mid Cap Growth Fund | 1,116,674 | 1.10% | $188.20M | 1.42% | Jun 30, 2026 |
| iShares Biotechnology ETF | 700,051 | 0.69% | $117.98M | 1.30% | Jun 30, 2026 |
| Vanguard Explorer Fund | 637,614 | 0.63% | $106.35M | 0.48% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 618,966 | 0.61% | $104.32M | 0.97% | Jun 30, 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 601,519 | 0.59% | $101.38M | 0.90% | Jun 30, 2026 |
| Invesco S&P MidCap Quality ETF | 599,829 | 0.59% | $100.05M | 1.84% | Jul 31, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 588,847 | 0.58% | $99.24M | 3.53% | Jun 30, 2026 |
| iShares MSCI USA Min Vol Factor ETF | 527,782 | 0.52% | $88.03M | 0.37% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kyle Gano | Chief Executive Officer, Director | 153,880 | 0.15% | Sep 15, 2026 |
| David W. Boyer | Chief Corp. Affairs Officer | 8,722 | 0.01% | Sep 15, 2026 |
| Eric Benevich | Chief Commercial Officer | 67,297 | 0.07% | Sep 15, 2026 |
| Ingrid Delaet | Chief Regulatory Officer | 18,289 | 0.02% | Sep 15, 2026 |
| Darin Lippoldt | Chief Legal Officer | 59,212 | 0.06% | Sep 15, 2026 |
| Matt Abernethy | Chief Financial Officer | 42,808 | 0.04% | Sep 15, 2026 |
| Sanjay Chandru Keswani | Chief Medical Officer | 5,393 | 0.01% | Sep 15, 2026 |
| Julie Cooke | Chief Human Resources Officer | 24,025 | 0.02% | Sep 15, 2026 |
| Jude Onyia | Chief Scientific Officer | 22,647 | 0.02% | Sep 15, 2026 |
| Andrew Ratz | Chief Technical Operations Off | 1,018 | 0.00% | Mar 17, 2026 |
| Eiry Roberts | Chief Medical Officer | 35,640 | 0.04% | Feb 14, 2025 |
| Kevin Charles Gorman | Director | 517,797 | 0.51% | Sep 15, 2026 |
| Stephen A. Sherwin | Director | 14,860 | 0.01% | Sep 3, 2026 |
| Leslie V. Norwalk | Director | 2,430 | 0.00% | Jul 30, 2026 |
| Christine A. Poon | Director | 4,753 | 0.00% | May 29, 2026 |
| William H. Rastetter | Director | 43,678 | 0.04% | May 29, 2026 |
| George J. Morrow | Director | 10,386 | 0.01% | May 29, 2026 |
| Richard F. Pops | Director | 37,798 | 0.04% | May 29, 2026 |
| Shalini Sharp | Director | 4,088 | 0.00% | May 29, 2026 |
| Gary A. Lyons | Director | 122,141 | 0.12% | May 29, 2026 |
| Johanna Mercier | Director | 6,853 | 0.01% | May 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David W. Boyer Chief Corp. Affairs Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −826 | $157.45 | $130.05K | 8,722 |
| Matt Abernethy Chief Financial Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −2,311 | $157.20 | $363.29K | 42,808 |
| David W. Boyer Chief Corp. Affairs Officer | Sep 11, 2026 | Award | +3,587 | – | – | 11,484 |
| David W. Boyer Chief Corp. Affairs Officer | Sep 11, 2026 | Tax withholding | −1,936 | $156.22 | $302.44K | 9,548 |
| Eric Benevich Chief Commercial Officer | Sep 11, 2026 | Tax withholding | −3,386 | $156.22 | $528.96K | 67,297 |
| Eric Benevich Chief Commercial Officer | Sep 11, 2026 | Award | +6,275 | – | – | 70,683 |
| Matt Abernethy Chief Financial Officer | Sep 11, 2026 | Award | +5,020 | – | – | 47,828 |
| Matt Abernethy Chief Financial Officer | Sep 11, 2026 | Tax withholding | −2,709 | $156.22 | $423.20K | 45,119 |
| Julie Cooke Chief Human Resources Officer | Sep 11, 2026 | Tax withholding | −1,936 | $156.22 | $302.44K | 24,025 |
| Julie Cooke Chief Human Resources Officer | Sep 11, 2026 | Award | +3,587 | – | – | 25,961 |
| Jude Onyia Chief Scientific Officer | Sep 11, 2026 | Tax withholding | −1,936 | $156.22 | $302.44K | 22,647 |
| Jude Onyia Chief Scientific Officer | Sep 11, 2026 | Award | +3,587 | – | – | 24,583 |
| Kyle Gano Chief Executive Officer, Director | Sep 11, 2026 | Tax withholding | −3,386 | $156.22 | $528.96K | 153,880 |
| Kyle Gano Chief Executive Officer, Director | Sep 11, 2026 | Tax withholding | −994 | $156.22 | $155.28K | 154,728 |
| Kyle Gano Chief Executive Officer, Director | Sep 11, 2026 | Award | +1,842 | – | – | 155,722 |
| Kyle Gano Chief Executive Officer, Director | Sep 11, 2026 | Award | +6,275 | – | – | 157,266 |
| Sanjay Chandru Keswani Chief Medical Officer | Sep 11, 2026 | Award | +3,914 | – | – | 5,393 |
| Sanjay Chandru Keswani Chief Medical Officer | Sep 11, 2026 | Tax withholding | −2,112 | $156.22 | $329.94K | 3,281 |
| Kevin Charles Gorman Director | Sep 11, 2026 | Tax withholding | −7,839 | $156.22 | $1.22M | 517,797 |
| Kevin Charles Gorman Director | Sep 11, 2026 | Award | +14,343 | – | – | 525,636 |
| Darin Lippoldt Chief Legal Officer | Sep 11, 2026 | Award | +4,483 | – | – | 59,212 |
| Darin Lippoldt Chief Legal Officer | Sep 11, 2026 | Tax withholding | −2,419 | $156.22 | $377.90K | 56,793 |
| Ingrid Delaet Chief Regulatory Officer | Sep 11, 2026 | Tax withholding | −2,419 | $156.22 | $377.90K | 18,289 |
| Ingrid Delaet Chief Regulatory Officer | Sep 11, 2026 | Award | +4,483 | – | – | 20,708 |
| Eric Benevich Chief Commercial Officer | Sep 9, 2026 | Sale(10b5-1 plan) | −2,154 | $154.61 | $333.03K | 64,408 |
| Eric Benevich Chief Commercial Officer | Sep 9, 2026 | Option exercise | +3,194 | $43.24 | $138.11K | 66,562 |
| Stephen A. Sherwin Director | Sep 2, 2026 | Gift | −1,000 | – | – | 14,860 |
| Jude Onyia Chief Scientific Officer | Aug 4, 2026 | Gift | −2,409 | – | – | 20,996 |
| Leslie V. Norwalk Director | Jul 29, 2026 | Option exercise | +842 | $139.43 | $117.40K | 2,430 |
| Leslie V. Norwalk Director | Jul 28, 2026 | Sale(10b5-1 plan) | −1,250 | $182.01 | $227.51K | 1,588 |
| Ingrid Delaet Chief Regulatory Officer | Jul 10, 2026 | Sale(10b5-1 plan) | −4,367 | $181.02 | $790.51K | 16,225 |
| Ingrid Delaet Chief Regulatory Officer | Jul 10, 2026 | Option exercise | +4,367 | $106.02 | $462.99K | 20,592 |
| Darin Lippoldt Chief Legal Officer | Jul 9, 2026 | Sale(10b5-1 plan) | −10,000 | $179.60 | $1.80M | 54,729 |
| Darin Lippoldt Chief Legal Officer | Jul 9, 2026 | Option exercise | +10,000 | $81.49 | $814.90K | 64,729 |
| Ingrid Delaet Chief Regulatory Officer | Jul 9, 2026 | Sale(10b5-1 plan) | −8,433 | $178.72 | $1.51M | 16,225 |
| Ingrid Delaet Chief Regulatory Officer | Jul 9, 2026 | Option exercise | +8,433 | $103.52 | $872.98K | 24,658 |
| Ingrid Delaet Chief Regulatory Officer | Jul 8, 2026 | Option exercise | +2,737 | $103.52 | $283.33K | 18,962 |
| Ingrid Delaet Chief Regulatory Officer | Jul 8, 2026 | Sale(10b5-1 plan) | −2,737 | $178.54 | $488.66K | 16,225 |
| Ingrid Delaet Chief Regulatory Officer | Jul 7, 2026 | Sale(10b5-1 plan) | −3,401 | $178.57 | $607.32K | 16,225 |
| Ingrid Delaet Chief Regulatory Officer | Jul 7, 2026 | Option exercise | +3,401 | $103.52 | $352.07K | 19,626 |
| Darin Lippoldt Chief Legal Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −8,110 | $170.03 | $1.38M | 54,729 |
| Darin Lippoldt Chief Legal Officer | Jun 29, 2026 | Option exercise | +8,110 | $81.49 | $660.88K | 62,839 |
| Darin Lippoldt Chief Legal Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −1,690 | $170.81 | $288.67K | 54,729 |
| Darin Lippoldt Chief Legal Officer | Jun 29, 2026 | Option exercise | +1,690 | $81.49 | $137.72K | 56,419 |
| Darin Lippoldt Chief Legal Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −200 | $169.57 | $33.91K | 54,729 |
| Darin Lippoldt Chief Legal Officer | Jun 26, 2026 | Option exercise | +200 | $81.49 | $16.30K | 54,929 |
| Jude Onyia Chief Scientific Officer | Jun 5, 2026 | Gift | −2,441 | – | – | 23,405 |
| Stephen A. Sherwin Director | Jun 5, 2026 | Sale(10b5-1 plan) | −1,843 | $167.31 | $308.35K | 15,860 |
| Stephen A. Sherwin Director | Jun 5, 2026 | Sale(10b5-1 plan) | −5,829 | $166.56 | $970.88K | 17,703 |
| Stephen A. Sherwin Director | Jun 5, 2026 | Sale(10b5-1 plan) | −6,896 | $165.79 | $1.14M | 23,532 |
| Stephen A. Sherwin Director | Jun 5, 2026 | Sale(10b5-1 plan) | −2,549 | $164.44 | $419.16K | 30,428 |
| Stephen A. Sherwin Director | Jun 5, 2026 | Sale(10b5-1 plan) | −7,883 | $163.81 | $1.29M | 32,977 |
| Stephen A. Sherwin Director | Jun 5, 2026 | Option exercise | +10,000 | $79.79 | $797.90K | 40,860 |
| Stephen A. Sherwin Director | Jun 5, 2026 | Option exercise | +15,000 | $53.64 | $804.60K | 30,860 |
| Leslie V. Norwalk Director | Jun 4, 2026 | Sale(10b5-1 plan) | −1,250 | $168.06 | $210.08K | 2,838 |
| Julie Cooke Chief Human Resources Officer | Jun 2, 2026 | Sale(10b5-1 plan) | −14,214 | $154.83 | $2.20M | 45,097 |
| Julie Cooke Chief Human Resources Officer | Jun 2, 2026 | Sale(10b5-1 plan) | −5,466 | $155.46 | $849.74K | 39,631 |
| Julie Cooke Chief Human Resources Officer | Jun 2, 2026 | Sale(10b5-1 plan) | −4,216 | $156.77 | $660.94K | 35,415 |
| Julie Cooke Chief Human Resources Officer | Jun 2, 2026 | Sale(10b5-1 plan) | −9,521 | $157.62 | $1.50M | 25,894 |
| Julie Cooke Chief Human Resources Officer | Jun 2, 2026 | Sale(10b5-1 plan) | −3,520 | $158.59 | $558.24K | 22,374 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Warren Boyer David Officer | Sep 14, 2026 | 4,714 | $736.42K | Sep 14, 2026 | Restricted and Performance Stock Units |
| C. Abernethy Matthew Officer | Sep 14, 2026 | 2,311 | $361.02K | Sep 14, 2026 | Performance Stock Units |
| Benevich Eric Officer | Sep 9, 2026 | 2,154 | $334.15K | Sep 9, 2026 | Exercise of Stock Options |
| Delaet Ingrid Officer | Jul 10, 2026 | 4,367 | $788.46K | Jul 10, 2026 | Exercise of Stock Options |
| Lippoldt Darin Officer | Jul 9, 2026 | 10,000 | $1.78M | Jul 9, 2026 | Exercise of Stock Options |
| Delaet Ingrid Officer | Jul 7, 2026 | 14,571 | $2.54M | Jul 7, 2026 | Exercise of Stock Options |
| Lippoldt Darin Officer | Jun 29, 2026 | 9,800 | $1.65M | Jun 29, 2026 | Exercise of Stock Options |
| Lippoldt Darin Officer | Jun 26, 2026 | 200 | $32.84K | Jun 26, 2026 | Exercise of Stock Options |
| Sherwin Stephen Director | Jun 5, 2026 | 25,000 | $4.18M | Jun 5, 2026 | Exercise of Stock Options |
| Cooke Julie Officer | Jun 2, 2026 | 36,937 | $5.95M | Jun 2, 2026 | Exercise of Stock Options |
| Onyia Jude Officer | Jun 1, 2026 | 11,000 | $1.74M | Jun 1, 2026 | Exercise of Stock Options |
| Delaet Ingrid Officer | May 29, 2026 | 2,261 | $353.60K | May 29, 2026 | Exercise of Stock Options |
| Onyia Jude Officer | May 27, 2026 | 11,000 | $1.71M | May 27, 2026 | Exercise of Stock Options |
| Warren Boyer David Officer | May 26, 2026 | 3,888 | $609.25K | May 26, 2026 | Restricted Stock Awards / Performance Stock Units |
| Charles Gorman Kevin Director | May 19, 2026 | 245,088 | $38.53M | May 19, 2026 | Previously Vested RSUs & PSUs |